inclusion criteria: 1. patients aged ≥ 18 years old. 2. a diagnosis of a confirmed, defined by a positive rt-pcr for sars cov-2, or suspected covid-19 disease, with suggestive findings on a chest ct scan. 3. patients on mechanical ventilation. 4. the presence of an informed consent signed by the next of kin. 5. patients with kdigo aki stage 2: defined by a rise in creatinine 2-2.9 times baseline and/or a urinary output less than 0.5 ml/kg/hr for 12 hours, with failure after a furosemide stress test. 6. the use of vasopressor, any dose. 7. complete medical history and complete laboratories.

inclusion criteria: 1. patients aged ≥ 18 years old. 2. a diagnosis of a confirmed, defined by a positive rt-pcr for sars cov-2, or suspected covid-19 disease, with suggestive findings on a chest ct scan. 3. patients on mechanical ventilation. 4. the presence of an informed consent signed by the next of kin. 5. patients with kdigo aki stage 2: defined by a rise in creatinine 2-2.9 times baseline and/or a urinary output less than 0.5 ml/kg/hr for 12 hours, with failure after a furosemide stress test. 6. the use of vasopressor, any dose. 7. complete medical history and complete laboratories.

inclusion criteria: patients aged ≥ 18 years old. a diagnosis of a confirmed, defined by a positive rt-pcr for sars cov-2, or suspected covid-19 disease, with suggestive findings on a chest ct scan. patients on mechanical ventilation. the presence of an informed consent signed by the next of kin. patients with kdigo aki stage 2: defined by a rise in creatinine 2-2.9 times baseline and/or a urinary output less than 0.5 ml/kg/hr for 12 hours, with failure after a furosemide stress test. the use of vasopressor, any dose. complete medical history and complete laboratories.

inclusion criteria: patients aged ≥ 18 years old. a diagnosis of a confirmed, defined by a positive rt-pcr for sars cov-2, or suspected covid-19 disease, with suggestive findings on a chest ct scan. patients on mechanical ventilation. the presence of an informed consent signed by the next of kin. patients with kdigo aki stage 2: defined by a rise in creatinine 2-2.9 times baseline and/or a urinary output less than 0.5 ml/kg/hr for 12 hours, with failure after a furosemide stress test. the use of vasopressor, any dose. complete medical history and complete laboratories.

inclusion criteria: 1. patients aged ≥ 18 years old. 2. a diagnosis of a confirmed, defined by a positive rt-pcr for sars cov-2, or suspected covid-19 disease, with suggestive findings on a chest ct scan. 3. patients on mechanical ventilation. 4. the presence of an informed consent signed by the next of kin. 5. patients with kdigo aki stage 2: defined by a rise in creatinine 2-2.9 times baseline and/or a urinary output less than 0.5 ml/kg/hr for 12 hours, with failure after a furosemide stress test. 6. the use of vasopressor, any dose. 7. complete medical history and complete laboratories.

inclusion criteria: 1. patients aged ≥ 18 years old. 2. a diagnosis of a confirmed, defined by a positive rt-pcr for sars cov-2, or suspected covid-19 disease, with suggestive findings on a chest ct scan. 3. patients on mechanical ventilation. 4. the presence of an informed consent signed by the next of kin. 5. patients with kdigo aki stage 2: defined by a rise in creatinine 2-2.9 times baseline and/or a urinary output less than 0.5 ml/kg/hr for 12 hours, with failure after a furosemide stress test. 6. the use of vasopressor, any dose. 7. complete medical history and complete laboratories.